- Home
- FTHM vs KLRS Comparison
FTHM vs KLRS Comparison
Compare FTHM & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | KLRS |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 46.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTHM | KLRS |
|---|---|---|
| Price | $0.96 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 230.6K | 65.3K |
| Earning Date | 03-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $421,612,000.00 | N/A |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.78 | N/A |
| 52 Week Low | $0.65 | $2.14 |
| 52 Week High | $3.37 | $12.90 |
Technical Indicators
Market Signals| Indicator | FTHM | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 42.21 |
| Support Level | $1.25 | $8.75 |
| Resistance Level | $1.30 | $9.48 |
| Average True Range (ATR) | 0.11 | 0.65 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 3.85 | 4.50 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.